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HIGHLIGHTS 
 COVID-19 is a viral disease caused by SARS-CoV-2. 
 Acute COVID-19 has 3 phases: early infection, pulmonary and severe hyperinflammation. 
 Thirteen autopsy cases demonstrate that COVID-19 is a systemic disease with major pulmonary 
and cardiac manifestations. 
 COVID-19 produces an interstitial pneumonia, usually with a prominent diffuse alveolar damage 
(DAD) component, often coupled with a thrombotic microangiopathy. 
 The heart frequently shows acute cardiomyocyte injury and, in some cases, pericarditis and/or 
myocarditis. 
 The spleen exhibits depletion of white pulp and expansion of red pulp with lymphoplasmacytic 
infiltrate. 
 Anatomic involvement of other organs is variable. 
 Patients with fatal COVID-19 frequently are obese and have pre-existing cardiac disease, 
hypertension and/or diabetes mellitus. 
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ABSTRACT 
This paper collates the pathological findings from initial published autopsy reports on 23 
patients with Coronavirus Disease 2019 (COVID-19) from 5 centers in the United States of 
America, including 3 cases from Houston, Texas.  Findings confirm that COVID-19 is a systemic 
disease with major involvement of the lungs and heart.  Acute COVID-19 pneumonia has 
features of a distinctive acute interstitial pneumonia with: a diffuse alveolar damage (DAD) 
component, coupled with microvascular involvement with intra- and extra-vascular fibrin 
deposition and intravascular trapping of neutrophils, and, frequently, with formation of 
microthombi in arterioles.  Major pulmonary thromboemboli with pulmonary infarcts and/or 
hemorrhage occurred in 5 of the 23 patients.  Two of the Houston cases had interstitial 
pneumonia with DAD pattern. One of the Houston cases had multiple bilateral segmental 
pulmonary thromboemboli with infarcts and hemorrhages coupled with, in non-hemorrhagic 
areas, a distinctive interstitial lymphocytic pneumonitis with intra-alveolar fibrin deposits and 
no hyaline membranes, possibly representing a transition form to acute fibrinous and 
organizing pneumonia (AFOP).  Multifocal acute injury of cardiac myocytes was frequently 
observed.  Lymphocytic myocarditis was reported in 1 case.  In addition to major pulmonary 
pathology, the three Houston cases had evidence of lymphocytic pericarditis, multifocal acute 
injury of cardiomyocytes without inflammatory cellular infiltrates, depletion of splenic white 
pulp, focal hepatocellular degeneration and rare glomerular capillary thrombosis. Each had 
evidence of chronic cardiac disease: hypertensive left ventricular hypertrophy (420 gram heart), 
dilated cardiomyopathy (1070 gram heart), and hypertrophic cardiomyopathy (670 gram heart).   
All three subjects were obese (BMIs of 33.8, 51.65 and 35.2 Kg/m2). Overall, the autopsy 
findings support the concept that the pathogenesis of severe COVID-19 disease involves direct 
viral-induced injury of multiple organs, including heart and lungs, coupled with the 
consequences of a procoagulant state with coagulopathy.  
KEY WORDS: COVID-19, SARS-CoV-2, Autopsy, Diffuse Alveolar Damage, Viral Pneumonia, 
Heart, Spleen, Liver, Kidney, Coagulopathy 
Word Count: 10794  
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I. INTRODUCTION  
 
A pneumonia of unknown cause was detected in Wuhan, China and was first reported to the 
World Health Organization (WHO) Country Office in China on 31 December 2019 (1).  The 
outbreak was identified as a Public Health Emergency of International Concern on 30 January 
2020 and was declared a pandemic on March 11, 2020 (2).  On 11 February 2020, WHO 
announced a name for the new coronavirus disease: COVID-19.  The causative virus was 
identified and designated as SARS-CoV-2. (3,4).  Clinical reports from China have established 
that COVID-19 presents as an acute febrile respiratory illness as the dominant feature of a 
systemic disease involving multiple organ systems (5, 6). 
 
 
As the pandemic spread resulting in major morbidity and mortality, it became crystal clear to 
medically oriented pathologists, forensic pathologists and allied pulmonologists, cardiologists, 
and critical care physicians that autopsy of deceased victims of the disease was of paramount 
importance for gaining knowledge of its pathogenesis and pathophysiology.  In a letter to the 
editor of Chest, Xu, Barth and Buja raised a call to action, specifically for as many autopsies to 
be done as soon as possible to determine the pathologic substrate of this disease (7). This is 
based on the well documented importance of the autopsy in establishing the etiology, 
pathogenesis and response to treatment of emerging diseases (8). 
 However, pronouncements by regulatory agencies in the USA have led to confusion, delay and, 
all too often, suppression of the performance of autopsies at many institutions.  Specifically, 
the Occupational Safety and Health Administration (OSHA) initially issued a contradictory 
statement with one sentence recommending suspension of post mortem procedures in 
suspected or confirmed COVID-19 cases and a second sentence indicating that, if deemed 
necessary and appropriate, strict adherence to basic safety procedures be used while 
performing such autopsies. In a subsequent statement from OSHA the first sentence was 
dropped (9).  The Centers for Disease Control (CDC) issued extensive guidelines which included 
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rigorous standards for morgues and autopsy facilities to be under negative pressure with 
specific standards for venting the air from the rooms (10).  There followed a spectrum of 
administrative responses to the OSHA and CDC directives. But the overall effect has been to 
create more than necessary impediments for the task before us. Of note and particular 
relevance for the autopsy situation, Dr. Patricia Harris, President of the American Medical 
Association, has issued an important statement defending science in a time of fear and 
uncertainty (11). 
 Fortunately for scientific inquiry, several healthcare institutions and medical examiner 
jurisdictions have persisted in performing autopsies on suspected and confirmed COVID-19 
cases. Just as a spectrum of responses has occurred for hospital autopsies, the same applies to 
medical examiner autopsies. Medical death investigation in the USA is a local function.  It varies 
from state to state and from county to county.  There are statewide, county, and regional 
systems that have substantial differences in their medicolegal jurisdiction. These considerations 
will determine the extent of COVID-19 autopsies in medical examiner jurisdictions around the 
country.  A great service has been done by Dr. Alex Williamson of the Northwell Health System 
who has organized an autopsy working group and listserv for the sharing of information 
(awilliamson@northwell.edu). 
Despite the challenges, autopsy studies are being performed and beginning to be reported from 
several locations around the USA, including Houston, Texas.   The purposes of this paper are to 
collate and summarize the findings from these autopsy studies, including our own three initial 
cases, to correlate them with emerging clinical information, and to provide thoughts about how 
this information may help with designing treatment strategies.  Correlation with information 
emerging from China, Europe and other countries also is touched upon. 
II. EARLY REPORTS FROM CHINA 
Liu et al. reported on an 85-year-old Chinese male who died following COVID-19 infection (12). 
The report was limited to gross autopsy findings of heavy lungs with copious amounts of grey-
white viscous fluid and unremarkable heart, liver and kidneys.  Xu et al. performed post-
mortem sampling (“biopsies”) of tissue from a 50-year-old man who died as a result of COVID-
19 infection (13).  Both lungs demonstrated changes consistent with diffuse alveolar damage 
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(DAD), the pathological correlate of acute respiratory distress syndrome (ARDS). The lungs 
showed interstitial lymphocytic infiltrates and atypical large pneumocytes with cytopathic 
changes consistent with a viral etiology. A few interstitial mononuclear inflammatory infiltrates 
were present in the heart and the liver showed moderate microvesicular steatosis. 
Tian et al. reported findings on two patients who underwent lung lobectomies for 
adenocarcinoma and were retrospectively found to have had COVID-19 infection at the time of 
surgery (14). On computed tomography (CT) scan, both patients exhibited bilateral ground glass 
opacities in the peripheral regions of the lungs.  Histopathologically, the lungs of both patients 
exhibited edema, proteinaceous exudate, focal hyperplasia of pneumocytes, patchy 
inflammatory cellular infiltration, some multinucleated giant cells, and focal intra-alveolar fibrin 
deposits.  Since neither patient had symptoms of pneumonia at the time of surgery, Tian et al. 
proposed that the changes likely represent an early phase of the lung pathology of COVID-19 
pneumonia (14).  
III. FINDINGS FROM INITIAL AUTOPSY SERIES IN THE USA (TABLES 1 and 2) 
Two cases have been reported from the Office of the Chief Medical Examiner, Oklahoma City, 
OK (15).  The decedents were a 77-year-old obese man and a 42-year-old obese man both of 
whom had positive postmortem nasopharyngeal swab tests for SARS-CoV-2.   The first patient 
had a history of hypertension, splenectomy and 6 days of fever and chills. The second patient 
was obese, had a history of myotonic dystrophy and developed abdominal pain followed by 
fever, shortness of breath and cough.  Both of the deceased died outside of the hospital, and 
the autopsies showed evidence of emergency medical intervention, including intubation and 
chest compressions. Combined weight of the lungs was 2,452 grams for the first case and 1,191 
grams for the second case.  On histopathology, the lungs of the first case showed evidence of 
“DAD in the acute stage characterized by numerous hyaline membranes without evidence of 
interstitial organization. There was very patchy and sparse interstitial chronic/lymphocytic 
inflammation, and chronic inflammation and edema in the bronchial mucosa.  A few small 
thrombi were noted within a few small pulmonary artery branches.” Focal acute cardiomyocyte 
damage labeled as ischemic injury was found.  Pulmonary pathology of the second case was 
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dominated by acute bronchopneumonia with evidence of aspiration.  Neither autopsy revealed 
viral inclusions, mucus plugging in airways, eosinophils, or myocarditis. The first case had a 402 
g heart, marked 2 vessel coronary artery disease, and microscopic evidence of acute ischemic 
injury.  The second case had a 372 gram heart with no evidence of coronary artery disease or 
myocardial damage. The brains were reported as showing no gross abnormalities. 
Four cases have been reported from the Department of Pathology of LSU Health Sciences 
Center, New Orleans, LA (16).  “The four decedents included male and female patients, ages 44-
76.  All were African American, and had histories of obesity class 2-3, and hypertension, 
controlled by medication.  Three of the patients had insulin-dependent type II diabetes, two 
had known chronic kidney disease (stages 2 and 3) and one was taking methotrexate. In all 
cases the clinical course consisted of approximately three days of mild cough and fever, with 
sudden respiratory decompensation just prior to arrival in the emergency department.  Chest 
radiographs revealed bilateral ground-glass opacities consistent with ARDS which worsened 
over the hospital course. The patients were intubated and brought to the Intensive Care Unit. 
Whether the patients were placed on ventilators was not specifically stated.  All of the patients 
tested positive for SARS-CoV-2 by 2019 Novel Coronavirus Real Time RT-PCR. Notable 
laboratory findings were the development of elevated ferritin, fibrinogen, prothrombin time, 
and within 24 hours of death, an increased neutrophil count with relative lymphopenia.  D-
dimers drawn near the time of death were markedly elevated (1200-2900 ng/mL).”  
“All of the lungs were heavy (680 - 1030 grams for left lungs and 800 - 1050 grams for right 
lungs). The pulmonary arteries at the hilum of each of the lungs were free of thromboemboli.  
The parenchyma of each of the lungs was diffusely edematous and firm, consistent with the 
clinical diagnosis of ARDS. Notably, regions of multifocal dark-colored hemorrhage were 
prominent. In some cases, small, firm thrombi were present in sections of the peripheral 
parenchyma on gross examination.  Major histological findings were bilateral DAD with 
multifocal hyaline membranes; a comparatively mild-to-moderate lymphocytic infiltrate, 
composed of a mixture of CD4+ and CD8+ lymphocytes; and desquamated type 2-pneumocytes 
with apparent viral cytopathic effect consisting of cytomegaly, and enlarged nuclei with bright, 
eosinophilic nucleoli. The alveolar capillaries were notably thickened, with surrounding edema, 
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and fibrin thrombi were present within capillaries and small vessels.  A notable finding was the 
presence of CD61+ megakaryocytes, possibly representing resident pulmonary megakaryocytes, 
with significant nuclear hyperchromasia and atypia. These cells were found within alveolar 
capillaries, often in association with, and actively producing platelets.  The fibrin and platelets 
present within small vessels also appeared to aggregate inflammatory cells, with entrapment of 
numerous neutrophils.”  With the exception of the patient on immunosuppression, no 
significant neutrophilic infiltrate was found within alveoli or the interstitium to suggest 
secondary infection.  
“Examination of the heart was performed in three cases, with the hearts ranging in size from 
430 to 550 grams (normal: 365grams +/- 71). The most significant findings were cardiomegaly, 
and right ventricular dilatation.  No case had significant coronary artery stenosis or thrombosis. 
Histologically, the sections of myocardium did not show any large or confluent areas of 
myocyte necrosis.  However, there was scattered individual cell myocyte necrosis in each heart 
examined.  Rare interstitial small collections of lymphocytes were seen. There was no 
significant brisk lymphocytic inflammatory infiltrate consistent with the typical pattern of viral 
myocarditis.”  
“The relative distribution of dsDNA and RNA in tissue sections was examined with DRAQ5 and 
SYTO RNA Select fluorescent staining (16).  Virally-infected cells in alveolar spaces showed 
multinucleation and grouping as evidenced by DNA stain, and abundant RNA present within the 
cytoplasm. Also noted was entrapment of immune cells, including degenerated neutrophils, 
within fibrin, and strands of extracellular material with weak DNA staining.” 
Histological and ultrastructural findings have been reported from autopsies on 12 fatal 
COVID-19 cases from the University of Washington in conjunction with the Kings County and 
Snohomish Medical Examiner Offices (17).  “All 12 patients were older with significant 
preexisting comorbidities. The major pulmonary finding was diffuse alveolar 
damage in the acute and/or organizing phases with virus identified in type I and 
II pneumocytes by electron microscopy. The kidney demonstrated viral particles 
in the tubular epithelium, endothelium, and podocytes without significant 
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inflammation. Viral particles were also observed in the trachea and large 
intestines. SARS-CoV-2 RNA was detected in the cardiac tissue of a patient with 
lymphocytic myocarditis. RT-PCR also detected viral RNA in the subcarinal lymph 
nodes, liver, spleen, and large intestines.”     
 
Two cases have been reported from the Icahn School of Medicine at Mount Sinai, New York, 
New York (18).  “The first patient, a middle-aged male with well-controlled hypertension, was 
admitted after 9 days with typical COVID-19 symptoms. A nasopharyngeal swab was positive for 
SARS-CoV-2 by real-time RT-PCR amplification for both the SARS-CoV-2 ORF1 a/b and pan-
Sarbecovirus E-gene, but the chest radiograph showed only mild bilateral pulmonary vascular 
congestion.  He was treated for bacterial superinfection, with some improvement, but 
continued to require supplemental nasal oxygen.  Serum ferritin and C-reactive protein were 
elevated. Repeat chest radiograph on hospital day 8 revealed new dense patchy left mid-lung 
and retrocardiac opacities, and a hazy opacity in the right lower lung.  On day 9, the patient 
complained of increasing left inspiratory chest pain and tenderness, and 30 minutes later 
developed pulseless electrical activity.” 
“The second patient, a middle-aged male with asthma, hypertension and human 
immunodeficiency virus (HIV) infection controlled on highly-active antiretroviral therapy, was 
admitted with a 2-day respiratory illness history.  A nasopharyngeal swab was positive for SARS-
CoV-2.  He was febrile on admission, and chest radiography showed multiple bilateral lung 
opacities.  Elevated ferritin and C-reactive protein were noted. His condition deteriorated, 
requiring intubation and mechanical ventilator support. Eight days following admission he 
developed pulseless electrical activity.” 
“At autopsy, a common notable finding was pulmonary thromboembolism, with occlusion of 
the right main pulmonary artery in one case, and occlusion of both left and right pulmonary 
arteries in the second. Deep venous thrombosis was found in both cases.  Other findings were 
multiple foci of pulmonary consolidation, cardiomegaly and left ventricular hypertrophy 
consistent with hypertensive cardiovascular disease. There was no mention of cardiomyocyte 
injury or myocarditis.” 
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“Ultrastructural examination demonstrated pleomorphic viral-like particles ranging from 60 to 
120 nm in distended cytoplasmic vacuoles within the pneumocytes in lung specimens from 
both cases.  The individual spherical viral-like particles displayed distinctive projections with 
mature particles exhibiting electron dense centers, consistent with the appearance of 
coronavirus.  Fibrin deposition within and outside capillaries as well as pure platelet thrombi 
also were noted. “ 
IV. HOUSTON CASES  
Case One was a moderately obese (BMI 33.8 Kg/m2) 62-year-old Hispanic man with a few-day 
history of respiratory illness who was found dead in his car.   A medicolegal autopsy was 
performed. Nasopharyngeal swab at the time of autopsy tested positive by RT-PCR for SARS-
CoV-2 virus.  Hepatitis panel (A, B, C) was negative.  The hemoglobin A1C was 7.0%. The lungs 
were heavy (right 820 grams, left 770 grams), but were free of major thromboemboli and 
hemorrhages.  Histologically, the picture was that of early DAD with multiple hyaline 
membranes accompanied by a focal and mild inflammation with modest numbers of CD3+ 
lymphocytes and more numerous CD68+ macrophages in some alveolar spaces (Figures 1 and 
2). There also were collections of reactive pneumocytes exhibiting cytomegaly, nucleomegaly 
with prominent nucleoli, and mitotic figures.  Some alveoli showed squamous metaplasia of the 
alveolar lining, presumably derived from the same reactive pneumocytes.  By 
immunohistochemistry, the pneumocytes in the alveoli were TTF-1 and CK-7 positive and the 
clusters showing squamous metaplasia were P40 and CK5/6 positive. Many alveolar capillaries 
contained megakaryocytes identified by large, hyperchromatic nuclei.  No microthrombi were 
identified on histological examination. 
Although no microthrombi were identified on light microscopic examination, electron 
microscopy revealed strands of precipitated fibrin and entrapped neutrophils within alveolar 
capillaries as well as larger deposits of fibrin in alveolar spaces (Figures 3-5).  No viral particles 
were identified in lungs or heart although cytological preservation was suboptimal. 
The heart weighed 420 grams and had patent coronary arteries with minimal atherosclerosis. 
The thickness of the left ventricular wall was 1.1 centimeters and that of the right ventricular 
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wall was 0.2-0.3 centimeters.  The myocardium showed cardiomyocytes with moderately 
enlarged hyperchromatic nuclei and individual cardiomyocytes with vacuolar degenerative 
change (Figure 6).  There was no evidence of inflammatory infiltrate indicative of myocarditis.  
By immunohistochemistry, there were 7-10 or less CD3+ T cells and rare CD68+ macrophages 
per high power field in the myocardium. Lymphocytic infiltrates composed of CD 3+ T cells with 
were present in the epicardium with a CD4/CD8 ratio of 2:1. (Figure 6). Random sections of the 
sinoatrial and atrioventricular conduction system showed no abnormalities. The liver showed 
moderate macrovesicular steatosis without evidence of hepatitis (Figure 6). The kidneys 
showed evidence of hyaline arteriolosclerosis with glomerulosclerosis.  The spleen was 
enlarged. There was expansion of the red pulp by congestion but also by a lymphoplasmacytic 
infiltrate (Figure 7). The white pulp was diminished and shrunken with absence of marginal 
zones. There were scattered immunoblasts near the edge of the small white pulp and scattered 
into the red pulp. There were no microthrombi or morphological features of vasculitis or a 
microangiopathic process. There were no macrophages with features of hemophagocytosis, 
thus no evidence for hemophagocytic lymphohistiocytosis (HLH). The brain was not examined. 
Case Two was a 34-year-old obese (BMI 51.65 Kg/m2) African-American man with a past 
medical history of hypertension, heart failure with reduced left ventricular ejection fraction 
(<20%), type II diabetes mellitus and microcytic anemia who presented to the emergency room 
after developing headache, shortness of breath, cough productive of bloody sputum for 4 days, 
and fever for 1 day. On admission , chest radiograph showed cardiomegaly and diffuse bilateral 
interstitial opacities in the lungs.  The CT chest findings included diffuse ground glass opacities 
of rounded morphology involving the upper and lower lobes of both lungs (Figure 8). The 
pulmonary artery was dilated at 3.4 cm (normal less than 3.15 cm) indicative of pulmonary 
hypertension. A pulmonary embolism was not identified. There was global cardiomegaly and a 
trace pericardial effusion. Electrocardiogram showed left ventricular hypertrophy with left axis 
deviation. The patient’s laboratory findings included white blood cell count of 4.0/µL with 
81.5% neutrophils (absolute 3.28), lymphocytes 12.4% (absolute 0.50), monocytes 5.2% 
(absolute 0.50) eosinophils 0.2%, and basophils 0.5%,  platelets 190/ µL, hemoglobin (Hg) 11.2 
g%, mean corpuscular volume (MCV) 70.8, and red cell distribution (RDW) 36. and mildly 
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elevated serum troponin with a peak of 0.22 ng/mL (normal < 0.045 ng/mL).  Hemoglobin A1c 
was 6.3%. On admission brain naturetic peptide (BNP) was 428 pg/mL and troponin was 0.09 
ng/mL (normal <0.045 ng/mL). Troponin later peaked at 0.22 ng/mL. Ferritin, D-dimer, 
prothrombin time, and partial thomboplastin time were not measured. Creatinine on admission 
was 1.0 mg/dL (normal 0.7-1.3 mg/dL) and remained normal until a final reading of 2.4 mg/dL. 
The patient was initially treated with antibiotics which was deescalated to supportive case 
when the nasopharyngeal swab test (RT-PCR) came back positive for SARS-CoV-2 virus. Tests for 
influenza and respiratory syncytial virus were negative. Working diagnoses in addition to 
COVID-19 infection were non-ischemic cardiomyopathy (NYHA class 3) with acute on chronic 
combined systolic and diastolic heart failure. The patient had a 10-day hospital course marked 
by recurrent fever, episodes of hemoptysis and shortness of breath. He received supplemental 
oxygen at 3-5 liters per minute but he was never placed on a mechanical ventilator. On the day 
of his death, he experienced severe worsening of respiratory failure followed by pulseless 
electrical activity.  
At autopsy, the major gross findings were extremely congested lungs (1980 grams combined 
weight) with multiple bilateral segmental pulmonary thromboemboli and multiple areas of 
hemorrhage, confirmed histologically as acute, unorganized thrombi (Figure 9). The heart that 
weighed 1070 grams with four-chamber hypertrophy and dilatation and patent coronary 
arteries with minimal atherosclerosis.  The thickness of the left ventricular wall was 1.5-1.6 
centimeters and that of the right ventricular wall was 0.5 centimeters.  The brain was not 
examined. Histologically the myocardium showed epicardial lymphocytic infiltrates; 
cardiomyocyte hypertrophy; multifocal interstitial and replacement fibrosis; scattered damaged 
individual cardiomyocytes, and no inflammatory foci indicative of myocarditis (Figure 10).  By 
immunohistochemistry, there were 7-10 or less CD3+ T cells and rare CD68+ macrophages per 
high power field in the myocardium. Lymphocytic infiltrates composed of CD 3+ T cells with 
were present in the epicardium with a CD4/CD8 ratio of 2:1. Random sections of the sinoatrial 
and atrioventricular conduction system showed no abnormalities. The lungs showed multiple 
bilateral segmental acute thromboemboli with associated areas of pulmonary hemorrhage and 
infarction (Figure 9).  Away from these areas, the lungs showed evidence of an interstitial 
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lymphocytic pneumonitis with lymphocytic infiltrates around small blood vessels and in the 
walls of terminal bronchioles extending into alveolar septae (Figure 9). Microthrombi were 
found in some pulmonary arterioles. The alveoli contained multiple deposits of fibrin without 
well-formed hyaline membranes and clusters of pneumocytes.  By immunohistochemistry, the 
pneumocytes in the alveoli were TTF-1 and CK-7 positive and the clusters showing squamous 
metaplasia were P40 and CK5/6 positive. No microthrombi were identified.  The heart showed 
evidence of individual damaged cardiomyocytes.  No inflammatory infiltrates were present. The 
liver showed moderate macrosteatosis without inflammatory infiltrates.  The spleen showed 
features similar to the spleen of Case One with generalized reduction in amount of white pulp 
and no evidence of HLH. The kidneys showed an occasional fibrin-platelet thrombus in renal 
glomerular capillaries.  The testis exhibited thrombi in peri-testicular veins (Figure 10). The 
brain was not examined. 
Case Three was a 48-year-old obese (BMI 35.2 Kg/m2) Hispanic man who was found dead at his 
residence.  A medicolegal autopsy was performed.  Nasopharyngeal swab at the time of 
autopsy tested positive by RT-PCR for SARS-CoV-2 virus. Screen for influenza viruses was 
negative. On opening the body, purulent tan opaque watery fluid measuring 500 ml was found 
in the right pleural cavity. Yellow translucent deposits were focally present of the visceral 
pleura along the upper/middle interlobar fissure.  Organized tan to greenish exudate with 
fibrotic thickening was present along the parietal and visceral pleural surfaces of the lower 
lobe. These were features of an empyema.  The right lung was collapsed. Minimal fluid was 
found in the left pleural cavity, pericardial sac and peritoneal cavity. Bacterial cultures of the 
right pleural cavity and lung grew mixed flora consistent with postmortem contamination. The 
right and left lungs weighed 1020 and 960 grams, respectively.  The treacheobronchial tree was 
lined by a hyperemic red-brown mucosa with no mucous plugs. The major pulmonary arteries 
were free of thromboemboli.  The parenchyma of the lungs was dull red-brown and firm. The 
heart weighed 670 grams.  The coronary arteries showed minimal atherosclerosis and were 
widely patent. Both ventricles were dilated.  The thickness of the left ventricular free wall and 
interventricular septum was 1.6 centimeters and that of the right ventricle was 0.3 centimeters.  
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On histological examination, the right pleura exhibited a necro-inflammatory infiltrate overlying 
cellular granulation tissue confirming the diagnosis of empyema. The right lung showed 
evidence of atelectasis as well as evidence of DAD.  The DAD was more pronounced in the 
expanded left lung.  The changes consisted of multifocal hyaline membranes, intra-alveolar 
fibrinous exudate, abundant intra-capillary megakaryocytes, numerous intra-alveolar 
macrophages, and activated type II pneumocytes, along with some neutrophils and intra-
alveolar hemorrhage (Figure 11). 
Multifocal lymphocytic infiltrates were present in the epicardium.  CMC showed enlarged 
hyperchromatic nuclei.  Individual CMC showed changes of acute injury.  No inflammatory 
cellular infiltrates were found. Additionally, there were prominent foci of CMC disarray, 
particularly involving the superior portion of the interventricular septum.   Many of the 
intramural coronary arteries showed intimal and medical thickening with luminal narrowing.   
The myofiber disarray and intramural coronary vasculopathy are diagnostic features of 
hypertrophic cardiomyopathy.  Random sections of the sinoatrial and atrioventricular 
conduction system showed no abnormalities. 
The liver showed moderate macrovesicular steatosis, lymphoplasmacytic triaditis with portal 
fibrosis and early portal-portal bridging fibrosis. The kidneys showed mild hyaline 
arteriolosclerosis and periglomerular hyaline arteriolosclerosis with rare holosclerotic 
glomeruli. The spleen showed lymphocyte depletion in the white pulp with absence of marginal 
zones; the red pulp was expanded with congestion and hemorrhage; abundant plasma cells 
were present in the red pulp. The brain showed no significant histopathological change. 
 
 
V. DISCUSSION 
Va. General 
COVID-19 is a viral disease that involves multiple organ systems while usually presenting as an 
acute febrile respiratory illness (1-6, 19-31). Acute COVID-19 has three distinct phases: early 
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infection, pulmonary and severe hyperinflammation (31). Prognostic indicators of a more 
serious and potentially fatal course include older age, lymphopenia, elevated D-dimer level, 
elevated troponin levels and pre-existing cardiovascular disease, hypertension and diabetes 
mellitus (19-31).  The pulmonary and cardiovascular systems are majorly affected (29-31). 
In spite of obstacles, autopsies are being performed on COVID-19 patients.  We have 
summarized the first reports of small autopsy series, and added three cases from our 
experience in Houston.  The findings are summarized in Tables  1 and 2. From these initially 
reported cases, a spectrum of pathology of COVID-19 disease is emerging.  The picture will be 
enhanced as more cases are studied and reported. 
Based on clinicopathological correlation from these first 23 autopsy  cases, the following 
observations are made: 1) acute COVID-19 pneumonia, not complicated by prolonged 
hospitalization and ventilator therapy, is a viral interstitial pneumonia characterized by the 
early exudative phase of DAD  with endothelial and epithelial injury, hyaline membranes, 
reactive pneumocytes with viral cytopathic effect, and mild combined lymphocytic and 
histiocytic intra-alveolar inflammation (32-34);  2) after a course of several days, the pulmonary 
pathology may evolve to a lymphocytic interstitial pneumonitis with intra-alveolar fibrin 
deposits, which may represent a transition stage to acute fibrinous and organizing pneumonia 
(AFOP) (32, 35, 36); 3) the picture of early COVID-19 pulmonary disease is remarkably similar to 
the DAD described with SARS-CoV virus infection in which both acute interstitial pneumonitis 
with a DAD pattern and AFOP have been described (37, 38); 4) although not universally found, 
pulmonary microthrombi are common, consistent with the frequent development of a SARS-
CoV-2- induced hypercoagulable state (16); 5) major pulmonary thromboembolism is a 
common fatal complication (18);   6) cardiovascular disease is a frequent co-morbidity in fatal 
cases (18); 7) individual cardiomyocyte damage is frequent, probably as a result of  infection of 
endothelial cells, perivascular cells and/or cardiomyocytes (see below); 8) myocarditis is much 
less common than suggested by elevated serum troponin levels, particularly if high sensitivity 
troponin is used (39-43); 9) depletion of white pulp of the spleen occurs as a correlate of the 
lymphopenia; 10) frequency and severity of target organ involvement in this systemic disease is 
linked to the distribution of the ACE-2 receptor for the virus (3, 4, 29-31);  11) the frequent co-
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infection with influenza and other viruses makes for difficulties in determining the direct effects 
of the SARS-CoV-2 virus (44); 12) antibody-dependent enhancement (ADE) may be important in 
determining the variable response to SARS-CoV-2 viral infection (45, 46) ; 13) treatment 
strategies should be guided by insights into the pathogenesis and pathophysiology of the 
disease provided by autopsy studies. 
Vb. Pulmonary System 
High confidence imaging findings on CT in patients with COVID-19 in the early phase include 
peripheral and bilateral ground glass opacities sometimes demonstrating a rounded 
morphology (47-49). This pattern of imaging is classically seen with evolving pneumonia 
explaining the causative pattern of lung injury. With disease progression, more areas of 
consolidation are seen that can progress to diffuse multifocal airspace disease as seen with DAD 
and ARDS (46-50). Imaging patterns that suggest an alternative diagnosis include a lobar 
pattern of consolidation, discrete pulmonary micronodules, pleural effusions and 
lymphadenopathy. Although the bilateral peripheral distribution of opacities is considered to be 
characteristic of COVID-19, other viral pneumonias, including those produced by certain strains 
of influenza, also can have a bilateral distribution of radiographic findings (51, 52). 
  From the analysis of autopsy findings in fatal COVID-19 cases, the pathological correlate of the  
imaging findings  seen  early in the course of COVID-19 is the distinctive interstitial pneumonia 
with DAD pattern. This COVID-19 interstitial pneumonitis can be accompanied by small vessel 
thrombi with associated hemorrhage in the lung periphery (16).  The COVID-19 interstitial 
pneumonitis also may be complicated and masked by multiple pulmonary thomboemboli 
(Houston Case Two and the two Mt. Sinai cases).   
The pathogenesis of COVID-19 pulmonary disease involves binding of SARS-CoV-2 virus to ACE-
2 receptors to pneumocytes and endothelial cells leading to development of acute lung injury 
manifest as DAD (3,4, 29).  The inflammatory reaction in DAD involves endothelial cell damage, 
capillary leak, activation of type II pneumocytes, and involvement of polarized pulmonary 
macrophages (32-34, 53-57).  There is also evidence for a role for pulmonary thrombotic 
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microangiopathy in COVID-19 pulmonary disease (16). The pathophysiology of disease 
progression likely involves hypoxic pulmonary vasoconstriction (58).  
Also, the possible relationships and merging of the patterns of DAD and organizing pneumonia 
(OP), also known as bronchiolitis obliterans combined organizing pneumonia (BOOP) and 
cryptogenic organizing pneumonia (COP), as well as a variant know as acute fibrinous and 
organizing pneumonia (AFOP), need further study (32-36, 59).   The dominant feature of AFOP 
is intra-alveolar fibrin “balls” or aggregates, typically in a patchy distribution. Organizing 
pneumonia in the form of luminal loose fibroblastic tissue is present surrounding the fibrin (32-
34). Hyaline membranes are absent.  The acute interstitial pneumonia of Hamman-Rich 
syndrome is characterized by the simultaneous presence of both acute and organizing DAD (32, 
59).  
Copin et al. recently have reported the findings from postmortem biopsies in 6 patients (36).  
The one patient who died after a 5-day course showed a lymphocytic viral pneumonia with DAD 
pattern. The 5 other patients who died after about 20 days of symptoms had the histological 
pattern of AFOP.  Correlation with pathophysiological showed that the first patient had a type L 
pattern of low pulmonary elastance whereas the other 5 patients had a type H pattern of high 
pulmonary elastance. Our patient who died after a 10-14-day course had a lymphocytic 
interstitial pneumonitis with intra-alveolar fibrin deposits and no hyaline membranes or foci of 
organizing pneumonia.  This pattern may represent a transition from the DAD to the AFOP 
patterns.  Interstitial pneumonitis with DAD and AFOP patterns has been described in the 
original SARS disease. Going forward, more extensive and detailed correlation of the clinical, 
imaging and pathological changes of the pulmonary component of COVID-19 is needed. 
Vc. Cardiovascular System 
The cardiovascular system is majorly impacted in many patients with COVID-19 disease.  Clinical 
features are indicative of acute myocardial injury as manifested by elevated serum troponin 
level, arrhythmias and ST segment elevation and/or depression on electrocardiogram in the 
absence of obstructive coronary artery disease (29-31, 60-64). 
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Tavazzi et al. obtained an endomyocardial biopsy (EMB) from a 69-year-old patent with a flu-
like illness due to SARS-CoV-2 infection that was successfully treated with venous-arterial 
extracorporeal membrane oxygenation (VA-ECMO) and mechanical ventilation.  
Endomyocardial biopsy (EMB) demonstrated low-grade myocardial inflammation and viral 
particles in the myocardial interstitial cells but not in cardiomyocytes or endothelial cells (65). 
The ultrastructural study demonstrated single or small groups of viral particles with the 
morphology ( dense round viral envelope and electron-dense spike-like structures on their 
surface) and size (variable between 70 and 120 nm) of coronaviruses (66). The authors 
interpreted the findings as evidence of direct involvement of the myocardium during a viremic 
phase or migration of infected macrophages from the lung. Grimes et al. demonstrated 60 to 
120 nm “viral-like” particles in distended cytoplasmic vacuoles within pneumocytes as well as 
rupture of the cytoplasmic vacuoles with release of the virus-like particles into the alveolar 
lumen (18).  The individual spherical viral-like particles had distinctive projections with mature 
particles exhibiting electron dense centers, consistent with the appearance of coronaviruses. 
Mild to moderate troponin elevations, particularly if measured by the high sensitivity troponin 
assays (hs-Tn), must be interpreted with caution regarding the magnitude of myocardial injury 
and may not reflect extensive irreversible myocardial injury due to myocardial ischemia or 
myocardial inflammation.  Overt myocarditis, characterized by inflammatory cellular infiltrates 
with associated cardiomyocyte damage, does occur with COVID-19 infection but is much less 
common than suggested by overinterpretation of troponin levels (39-43). Right heart strain 
with pulmonary thromboembolism also can be associated with elevated troponin level. 
Chen et al. hypothesized that pericytes may be infected by the SARS-CoV-2 virus and cause 
capillary endothelial cell and microvascular dysfunction that may cause individual cardiomyocte 
necrosis. This can explain the frequent occurrence of mild to moderate troponin elevations in 
patients with COVID-19 (67). Direct involvement of coronary arteries in viral infections has been 
considered in the pathogenesis of clinical cardiac manifestations of these diseases (68).  
However, inflammation of the coronary arteries has not been observed in the Houston COVID-
19 autopsy cases. Another manifestation of cardiac involvement in COVID-19 may be stress 
induced, i.e., Takotsubo cardiomyopathy (69, 70). 
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Pre-existing heart disease, diabetes mellitus and obesity clearly predispose to adverse outcome 
from COVID-19 infection.  Of note, the three Houston cases were obese men with  evidence of 
chronic heart disease: hypertension-related left ventricular hypertrophy, dilated 
cardiomyopathy and hypertrophic cardiomyopathy. The nature of the interactions requires 
further study.  Another phenomenon is that the COVID-19 pandemic is causing patients with 
acute coronary syndromes (ACS) to delay obtaining treatment or avoid presenting to the 
hospital for medical attention, with potentially fatal consequences (62). Patients with cardiac 
transplants may be at particularly increased risk (71). 
Influenza infection imparts an increased risk for acute myocardial infarction and sudden cardiac 
death in subsequent months following the acute illness. It is important to determine if COVID-
19 infection imparts a similar risk for subsequent cardiovascular events (72, 73). 
Vd. Systemic Manifestations of COVID-19 
COVID-19 infection of organs is initiated by binding of the virus to the ACE-2 receptor on a cell 
(3, 4, 29-31, 67).  Thus, the distribution of the ACE-2 receptor in various cell types in different 
organs determines the involvement of these sites in the progression of COVID-19.  The diseases 
progresses from a pulmonary infection to a systemic disease.  In addition to heart and lung, 
target organ involvement of brain stem, liver and kidneys have been reported (74-77).  In this 
report, involvement of the spleen is documented.  Even though histological changes in the 
kidney are relatively mild, many COVID-19 patients are experiencing clinical features of acute 
renal injury and failure (77).  
 Clinical reports have associated severe pneumonia and fatal outcomes in SARS-CoV-2 with 
elevated levels of D-dimer and fibrin degradation products (FDP), suggesting derangement of 
coagulation activation and consequently a potential disposition to thromboembolic events. (19-
31).  Grimes et al. point out that several viral infections have been associated with coagulation 
disorders that may lead to thrombosis and disseminated intravascular coagulation (DIC) (18). 
Both influenza virus and SARS have been associated with pulmonary intravascular thrombi 
formation and fibrin deposition likely as a result of DIC and microthrombosis.  In SARS 
coronavirus infection, increased production of a novel pro-coagulant by infected cells due to 
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increased hfg12 gene transcription induced by viral nucleocapsid (N) protein has been proposed 
as a mechanism contributing to thrombosis (18, 78).  
Fox et al. noted pulmonary microvascular thrombi, CD4+ T cells around the thrombosed vessels, 
focal hemorrhages, abundant megakaryocytes in pulmonary capillaries, platelet aggregation, 
platelet-rich clots, associated entrapment of neutrophils, and fibrin deposits inside and outside 
of capillaries (16).  We also observed entrapment of neutrophils in capillaries and fibrin 
deposits within and outside of capillaries.  We concur with the suggestion of Fox et al that an 
important pathogenic mechanism of fatal COVID-19 disease is a thrombotic microangiopathy 
primarily involving the lungs. Variation in the demonstration of microthombi in the lungs may 
relate to the stage of the coagulopathy at the time of death.  In DIC, microthrombi are found in 
multiple organs in relationship to the peak of clot formation but may not be found when the 
DIC has progressed to depletion of clotting factors and activation of fibrinolysis (79-83). 
Endothelial cell infection has been noted in at least two studies (17, 84).  Endothelial cell 
infection and endotheliitis appears to be an important underlying mechanism linked to vascular 
dysfunction and thrombotic events in the lung, kidney and possibly the heart and other organs 
(67, 84). 
 
IVe. Conclusions 
Autopsy studies have established that COVID-19 is a systemic disease with major involvement 
of the cardiovascular and pulmonary systems and with the expected accompaniment of major 
activation of the inflammatory and immune systems (81, 85).  The autopsy studies also provide 
evidence that SARS-COV-2 patients have a baseline hypercoagulable state and are at increased 
risk for pulmonary thrombotic microangiopathy as well as the development of deep vein 
thromboses and major pulmonary thromboembolism.  The autopsy findings support evaluation 
and management for coagulopathy early in the course of disease and judicious use of 
prophylactic anticoagulants while hospitalized (86-88). 
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The initial approach to acute therapy for COVID-19 patients with life-threatening respiratory 
failure has involved administration of supplemental oxygen, artificial ventilation and use of the 
extracorporeal membrane oxygenator (ECMO) when necessary (89).  Additional approaches 
and strategies for treatment of COVID-19 patients are actively being pursued, and they are 
clearly needed (36, 90-92).  Autopsies on COVID-19 patients need to continue to be performed 
to further elucidate the natural history of the disease and to guide the development of optimal 
therapeutic regimens.    
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Figure 1. Houston Case One (HC1). A. Pulmonary alveoli exhibit congested capillaries, hyaline 
membranes and increased numbers of mononuclear cells in the alveolar spaces.  B. Hyaline 
membranes resulting from capillary leak leading to fibrinous exudate and fibrin precipitate. C. 
Collection of pneumocytes showing squamous metaplasia. D. Alveoli exhibiting congested 
alveolar capillaries containing leukocytes (two arrows)  and a megakaryocyte with large 
hyperchromatic nucleus(single arrow) and alveolar spaces containing foamy macrophages of 
variable size. (A, B, C, D; Hematoxylin and eosin stains). (Magnification bar: A 200 µm; B, C, and 
D 20 µm). 
  
         
33 
 
 
Figure 2. HC1. Immunohistochemical findings for lung pathology. Alveoli contain a mildly 
increased number of CD3+ T lymphocytes (A), a moderately increased number of CD68+ 
macrophages (B) and increased numbers of TTF+ pneumocytes (C).  Clusters of pneumocytes 
exhibit squamous metaplasia as indicated by positive CK-7 expression (D).  (Magnification bar: 
A, B, C and D; 100 µm. 
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Figure 3. HC1. Electron micrographs.  A.  Alveolar capillaries contain erythrocytes and 
neutrophils identified by the presence of characteristic granules (red star). B. Higher 
magnification view of a portion of a neutrophil with characteristic granules. 
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Figure 4. HC1. Electron micrographs. A. Alveolar capillaries contain erythrocytes and strands of 
electron dense fibrin (arrows).  The edematous alveolar septum also has larger precipitates of 
fibrin outside of the capillary (stars). The alveolar lining cells have been lost. B. Higher 
magnification view of fibrin deposit within an alveolar capillary (star). 
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Figure 5. HC1. Electron micrographs. A. Large electron-dense, intra-alveolar fibrin deposits are 
in close apposition to the alveolar septum (arrow).  B. Higher magnification view of intra-
alveolar fibrin deposit intermixed with collagen fibrils. 
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Figure 6. HC1. A. Epicardium exhibits a focus with lymphocytic infiltrate indicative of 
lymphocytic pericarditis. B. Myocardium is edematous as manifest as separation of the 
cardiomyocytes (CMC) and capillaries.  The CMC in the center shows vacuolar degenerative 
change (star). No inflammatory cells are present. C. Liver shows moderate macro-steatosis and 
altered, shrunken hepatocytes likely representing incipient apoptosis. D. Renal glomerulus with 
focally congested capillaries. (A, C and D, Hematoxylin and eosin stains; B, one-micron section, 
toluidine blue stain).  Magnification bar: A and C, 100 µm; B and D, 20 µm). 
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Figure 7 HC1. Spleen. A. Expansion of red pulp and shrinking of white pulp with absent marginal 
zones. B. Red pulp with lymphoplasmacytic infiltrate. C.   White pulp with scattered 
immunoblasts. D. Red pulp with lymphoplasmacytic infiltrate. (Hematoxylin and eosin stains). 
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Figure 8. Houston Case Two (HCT). A and B.  Axial CT images which demonstrate bilateral upper 
and lower lobe ground-glass and early consolidative alveolar opacities some of rounded 
morphology, classically described with COVID-19. 
  
         
40 
 
    
 (a)   (b)   (c)   (d) 
Figure 9. Houston Case Two (HC2). A. Pulmonary thromboembolus obstructing segmental 
pulmonary artery; one of several in both lungs. B. Terminal bronchiole with interstitial 
lymphocytic infiltrates. C. Interstitial and intra-alveolar infiltrates composed predominantly of 
lymphocytes. D. Intra-alveolar fibrin deposit (star). The pulmonary arteriole has a thickened 
wall indicative of chronic pulmonary hypertension.  (A, B, C, D; Hematoxylin and eosin stains). 
(Magnification bar: A, 500 µm; B, 100 µm; C and D, 50 µm). 
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Figure 10. HC2. A and B. Myocardium is edematous and small blood vessels are congested. The 
CMC exhibit multifocal vacuolar degenerative changes.  No inflammatory cellular infiltrates are 
present.  Note the increased width of these CMC compared to those of HCO (Figure 6B). The 
patient’s heart weighed 1070 g. C. The epicardium exhibits a lymphocytic infiltrate adjacent to a 
vein. D. Testis with thrombi in peri-testicular veins. (A and B, one-micron sections, toluidine 
blue stain; C and D, hematoxylin and eosin stains). (Magnification bar: A and B, 20 µm; C, 100 
µm; D 500 µm). 
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Figure 11. Houston Case Three (HC3).  A. Pulmonary parenchyma showing interstitial 
pneumonia with DAD pattern. B. Bronchiole with fibrinous exudate. C. Alveolar capillaries 
contain numerous megakaryocytes with large hyperchromatic nuclei. D. Alveoli contain 
enlarged reactive pneumocytes and fibrin deposit. (A, B, C, and D; Hematoxylin and eosin 
stains). (Magnification bar: A, 200 µm; B, 100 µm; C and D, 20 µm). 
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TABLE 1. IMPORTANT FINDINGS IN TWENTY-THREE AUTOPSIES SUBJECTS WITH COVID-19 
Gender Male 12 
 Female 7 
 Not specified 4 
Ethnicity African-American 5 
 Hispanic 2 
 Not specified 16 
Age group Known: 34-76 21 
 Not Specified 2 
Comorbidities* Hypertension 10 
 Obesity 9 
 Type II diabetes Mellitus 5 
Pulmonary Pathology 23  
 Acute pneumonitis 20 
  Interstitial pneumonitis with DAD  
 Interstitial lymphocytic pneumonitis 
 Insipient interstitial pneumonitis 
 Bronchopneumonia with aspiration 
16 
1 
2 
1 
 Fibrin-rich thrombi in capillaries and small blood 
vessels 
6˜ 
 
 Large pulmonary thromboemboli 5 
Cardiac Pathology° 23  
 Cardiomegaly, ranging 420-1070 gms 13 
 Individual cardiomyocyte injury  8 
 Lymphocytic epicarditis/pericarditis 3 
 Lymphocytic myocarditis 1 
Splenic Pathology°+ 6  
 Diminished white pulp with loss of marginal zones 6 
 Expansion of red pulp with lymphoplasmacytic 
infiltrate 
3 
* Does not include WA cases (no specific data on number of cases/comorbidity provided). 
° No information about cardiac or splenic histology included in report from NY (report does note 
cardiomegaly in both cases).  
+ No information about splenic findings included in report from LA.  
˜ Includes Tx case #2 but does not include TX case #1 with intravascular fibrin aggregates seen only by 
EM.  
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TABLE 2. PATHOPHYSIOLOGICAL FACTORS IN COVID-19 DISEASE 
SYSTEMS OR ORGANS PATHOPHYSIOLOGICAL FACTORS 
PULMONARY  Viral uptake into vascular endothelium and pneumocytes 
 Distinctive interstitial pneumonia with intra- and extra-vascular 
fibrin deposition, activation of megakaryocytes, intravascular 
trapping of neutrophils, proliferation of type II pneumocytes, intra-
alveolar accumulation of lymphocytes and macrophages 
 Diffuse alveolar damage with overlapping phases, including 
hyaline membrane formation, alveolar fibrin deposits, hyper 
reactive type II pneumocytes with viral cytopathic effects, 
squamous metaplasia with syncytium, and later organizing phase  
 Thrombotic microangiopathy 
  Pulmonary thromboembolism 
CARDIOVASCULAR 
SYSTEM 
 Viral uptake into interstitial, perivascular and endothelial cells 
 Endotheliitis 
 Microvascular dysfunction 
 Direct or indirect damage to cardiomyocytes 
 Myocarditis in some cases 
 Pericarditis in some cases  
HEMATOLOGIC SYSTEM  Virus induced pro-coagulant stage and coagulopathy  
 Virus invasion and damage of T lymphocytes resulting in 
lymphopenia 
 Depletion of white pulp of the spleen 
 Predisposition to deep vein thrombosis and pulmonary 
thromboembolism 
 
         
